Al-Kali, Aref https://orcid.org/0000-0002-0824-3715
Nanaa, Ahmad https://orcid.org/0000-0001-5247-5065
Viswanatha, David
He, Rong https://orcid.org/0000-0001-6116-8163
Nguyen, Phuong
Jevremovic, Dragan https://orcid.org/0000-0002-1792-5822
Foran, James M. https://orcid.org/0000-0003-1673-1708
Yi, Cecelia Arana
Greipp, Patricia T. https://orcid.org/0000-0002-5536-9011
Gangat, Naseema https://orcid.org/0000-0002-9104-6172
Patnaik, Mrinal https://orcid.org/0000-0001-6998-662X
Tefferi, Ayalew https://orcid.org/0000-0003-4605-3821
Litzow, Mark R. https://orcid.org/0000-0002-9816-6302
Mangaonkar, Abhishek A. https://orcid.org/0000-0003-2458-9887
Shah, Mithun Vinod https://orcid.org/0000-0002-5359-336X
Badar, Talha https://orcid.org/0000-0003-1548-918X
Alkhateeb, Hassan B. https://orcid.org/0000-0002-3609-8404
Article History
Received: 24 November 2022
Revised: 4 March 2023
Accepted: 14 March 2023
First Online: 10 April 2023
Competing interests
: MVS: Research funding to institution: Astellas, Celgene, and Marker Therapeutics. Aref Al-Kali, MD: research funding to institution: Celgene/BMS.